Last reviewed · How we verify
Azithromycin 250 mg
Azithromycin 250 mg is a Small molecule drug developed by Centre Hospitalier Universitaire, Amiens. It is currently FDA-approved. Also known as: ZITHROMAX, Azro 250.
At a glance
| Generic name | Azithromycin 250 mg |
|---|---|
| Also known as | ZITHROMAX, Azro 250 |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (PHASE3)
- Azithromycin Reduction to Reach Elimination of Trachoma (PHASE4)
- Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis (PHASE3)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study of Standard Drugs for Mycobacterium Avium Complex (PHASE2)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Antibiotic Treatment of Recurrent Episodes of Asthma in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromycin 250 mg CI brief — competitive landscape report
- Azithromycin 250 mg updates RSS · CI watch RSS
- Centre Hospitalier Universitaire, Amiens portfolio CI
Frequently asked questions about Azithromycin 250 mg
What is Azithromycin 250 mg?
Azithromycin 250 mg is a Small molecule drug developed by Centre Hospitalier Universitaire, Amiens.
Who makes Azithromycin 250 mg?
Azithromycin 250 mg is developed and marketed by Centre Hospitalier Universitaire, Amiens (see full Centre Hospitalier Universitaire, Amiens pipeline at /company/centre-hospitalier-universitaire-amiens).
Is Azithromycin 250 mg also known as anything else?
Azithromycin 250 mg is also known as ZITHROMAX, Azro 250.
What development phase is Azithromycin 250 mg in?
Azithromycin 250 mg is FDA-approved (marketed).
Related
- Manufacturer: Centre Hospitalier Universitaire, Amiens — full pipeline
- Also known as: ZITHROMAX, Azro 250
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing